| Literature DB >> 34694418 |
Alejandra Tomás-Velázquez1, Onofre Sanmartin-Jiménez, Joan R Garcés, Manuel A Rodríguez-Prieto, Verónica Ruiz-Salas, Esther De Eusebio-Murillo, Román Miñano-Medrano, Begoña Escutia-Muñoz, Ángeles Flórez-Menéndez, Juan L Artola-Igarza, Alberto Alfaro-Rubio, Pilar Gil, Yolanda Delgado-Jiménez, Julia M Sanchez-Schmidt, Irati Allende-Markixana, María L Alonso-Pacheco, Beatriz García-Bracamonte, Pablo De la Cueva-Dobao, Raquel Navarro-Tejedor, Cristina Ciudad-Blanco, Lucía Carnero-González, Hugo Vázquez-Veiga, Natividad Cano-Martínez, Eva Vilarrasa-Rull, Pedro Sanchez-Sambucety, José L López-Estebaranz, Rafael Botella-Estrada, Beatriz Gonzalez-Sixto, Antonio Martorell-Calatayud, Victoriano Morales-Gordillo, Agustí Toll-Abelló, Izascun Ocerin-Guerra, Matías Mayor-Arenal, Ricardo Suárez-Fernández, Laura Sainz-Gaspar, Miguel A Descalzo, Ignacio García-Doval, Pedro Redondo.
Abstract
Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the "real-life" results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1-1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3-6.1), being constant over time (0-5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.Entities:
Mesh:
Year: 2021 PMID: 34694418 PMCID: PMC9455311 DOI: 10.2340/actadv.v101.544
Source DB: PubMed Journal: Acta Derm Venereol ISSN: 0001-5555 Impact factor: 3.875